Judith Ross1, Peter A Lee, Robert Gut, John Germak. 1. Department of Pediatrics, Thomas Jefferson University DuPont Hospital for Children, Philadelphia, Pa., USA. judith.ross@jefferson.edu
Abstract
BACKGROUND/AIMS: To assess height standard deviation scores (HSDS) in patients with Turner syndrome (TS) by age at treatment initiation and varying durations of treatment with growth hormone (GH). METHODS: GH treatment-naïve patients with TS from the American Norditropin Studies: Web-enabled Research (ANSWER) Program® Registry were analyzed at baseline, 4 months, and annually. RESULTS: Three hundred and eighty-two patients with TS had a baseline mean (±SD) HSDS of -2.6 ± 0.9. Patients received short-term (1 year), long-term (<3 years), and extended GH treatment (≥3 years, mean = 4.54 years), resulting in 40.2% (n = 99/246), 60.5% (n = 69/114), and 62.3% (n = 86/138) of the patients achieving HSDS >-2. Patients starting GH at a younger age experienced better growth response, regardless of treatment duration. Change in HSDS from baseline (ΔHSDS) at 4 months correlated positively with ΔHSDS at 1 and 3 years, and ΔHSDS at 1 year with ΔHSDS at 3 years (p values from 0.0017 to<0.0001). CONCLUSIONS: Height gains in patients with TS during short-term treatment were found to be highly predictive of longer-term results. Continuation of GH treatment (≥3 years) resulted in 62.3% of the patients achieving an HSDS within the normal population range, indicating the clinical importance of early initiation and continuation of GH treatment in patients with TS.
BACKGROUND/AIMS: To assess height standard deviation scores (HSDS) in patients with Turner syndrome (TS) by age at treatment initiation and varying durations of treatment with growth hormone (GH). METHODS: GH treatment-naïve patients with TS from the American Norditropin Studies: Web-enabled Research (ANSWER) Program® Registry were analyzed at baseline, 4 months, and annually. RESULTS: Three hundred and eighty-two patients with TS had a baseline mean (±SD) HSDS of -2.6 ± 0.9. Patients received short-term (1 year), long-term (<3 years), and extended GH treatment (≥3 years, mean = 4.54 years), resulting in 40.2% (n = 99/246), 60.5% (n = 69/114), and 62.3% (n = 86/138) of the patients achieving HSDS >-2. Patients starting GH at a younger age experienced better growth response, regardless of treatment duration. Change in HSDS from baseline (ΔHSDS) at 4 months correlated positively with ΔHSDS at 1 and 3 years, and ΔHSDS at 1 year with ΔHSDS at 3 years (p values from 0.0017 to<0.0001). CONCLUSIONS: Height gains in patients with TS during short-term treatment were found to be highly predictive of longer-term results. Continuation of GH treatment (≥3 years) resulted in 62.3% of the patients achieving an HSDS within the normal population range, indicating the clinical importance of early initiation and continuation of GH treatment in patients with TS.
Authors: Charlotte Höybye; Lars Sävendahl; Henrik Thybo Christesen; Peter Lee; Birgitte Tønnes Pedersen; Michael Schlumpf; John Germak; Judith Ross Journal: Clin Epidemiol Date: 2013-04-26 Impact factor: 4.790
Authors: Peter A Lee; Judith L Ross; Birgitte Tønnes Pedersen; Primoz Kotnik; John A Germak; Henrik T Christesen Journal: Int J Pediatr Endocrinol Date: 2015-09-08
Authors: David R Murdock; Frank X Donovan; Settara C Chandrasekharappa; Nicole Banks; Carolyn Bondy; Maximilian Muenke; Paul Kruszka Journal: J Clin Endocrinol Metab Date: 2017-05-01 Impact factor: 5.958
Authors: Jan M. Wit; Asma Deeb; Bassam Bin-Abbas; Angham Al Mutair; Ekaterina Koledova; Martin O. Savage Journal: J Clin Res Pediatr Endocrinol Date: 2019-07-09
Authors: Lars Sävendahl; Michel Polak; Philippe Backeljauw; Jo Blair; Bradley S Miller; Tilman R Rohrer; Alberto Pietropoli; Vlady Ostrow; Judith Ross Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958